Shira E Eisman
Overview
Explore the profile of Shira E Eisman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
104
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bowman R, Dunbar A, Mishra T, Xiao W, Waarts M, Maestre I, et al.
Cancer Cell
. 2024 Nov;
42(11):1955-1969.e7.
PMID: 39532065
Cancer evolution is a multifaceted process leading to dysregulation of cellular expansion and differentiation through somatic mutations and epigenetic dysfunction. Clonal expansion and evolution is driven by cell-intrinsic and -extrinsic...
2.
Waarts M, Mowla S, Boileau M, Martinez Benitez A, Sango J, Bagish M, et al.
Cancer Discov
. 2024 May;
14(10):1860-1878.
PMID: 38819218
Clonal hematopoiesis (CH) is a common premalignant state in the blood and confers an increased risk of blood cancers and all-cause mortality. Identification of therapeutic targets in CH has been...
3.
Shannon M, Eisman S, Lowe A, Sloan T, Mace E
J Cell Sci
. 2024 May;
137(20).
PMID: 38738282
Advances in imaging, segmentation and tracking have led to the routine generation of large and complex microscopy datasets. New tools are required to process this 'phenomics' type data. Here, we...
4.
Dunbar A, Bowman R, Park Y, OConnor K, Izzo F, Myers R, et al.
Cancer Discov
. 2024 Jan;
14(5):737-751.
PMID: 38230747
Significance: Current JAK inhibitors to treat myeloproliferative neoplasms are ineffective at eradicating mutant cells. We developed an endogenously expressed Jak2V617F dual-recombinase knock-in/knock-out model to investigate Jak2V617F oncogenic reversion in vivo....
5.
Nazaret A, Fan J, Lavallee V, Burdziak C, Cornish A, Kiseliovas V, et al.
bioRxiv
. 2023 Nov;
PMID: 38014231
Biological insights often depend on comparing conditions such as disease and health, yet we lack effective computational tools for integrating single-cell genomics data across conditions or characterizing transitions from normal...
6.
Shannon M, Eisman S, Lowe A, Sloan T, Mace E
bioRxiv
. 2023 Nov;
PMID: 37961659
Advances in imaging, cell segmentation, and cell tracking now routinely produce microscopy datasets of a size and complexity comparable to transcriptomics or proteomics. New tools are required to process this...
7.
Hegewisch-Solloa E, Melsen J, Ravichandran H, Rendeiro A, Freud A, Mundy-Bosse B, et al.
bioRxiv
. 2023 Sep;
PMID: 37732282
Natural killer (NK) cells develop from CD34+ progenitors in a stage-specific manner defined by changes in cell surface receptor expression and function. Secondary lymphoid tissues, including tonsil, are sites of...
8.
Martinez A, Shannon M, Eisman S, Hegewisch-Solloa E, Asif A, Ebrahim T, et al.
Methods Mol Biol
. 2022 Mar;
2463:129-151.
PMID: 35344172
Migration is an important function for natural killer cells. Cell motility has implications in development, tissue infiltration, and cytotoxicity, and measuring the properties of natural killer (NK) cell migration using...
9.
Viny A, Bowman R, Liu Y, Lavallee V, Eisman S, Xiao W, et al.
Cell Stem Cell
. 2019 Sep;
25(5):682-696.e8.
PMID: 31495782
Transcriptional regulators, including the cohesin complex member STAG2, are recurrently mutated in cancer. The role of STAG2 in gene regulation, hematopoiesis, and tumor suppression remains unresolved. We show that Stag2...